Publicaciones en colaboración con investigadores/as de Hospital del Mar (12)

2020

  1. Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study)

    BJU International, Vol. 126, Núm. 5, pp. 559-567

2019

  1. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132

2011

  1. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: Baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity

    Annals of Oncology, Vol. 22, Núm. 12, pp. 2646-2653

2010

  1. Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: Focus on special populations

    Cancer and Metastasis Reviews, Vol. 29, Núm. SUPPL. 1

  2. Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma

    Cancer and Metastasis Reviews, Vol. 29, Núm. SUPPL. 1

2009

  1. Recommendations from the Spanish oncology genitourinary group for the treatment of metastatic renal cancer

    Cancer Chemotherapy and Pharmacology

2007

  1. Gemcitabine and oxaliplatin combination: A multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer

    Annals of Oncology, Vol. 18, Núm. 8, pp. 1359-1362

  2. Sorafenib TARGET trial results in Spanish patients

    Clinical and Translational Oncology, Vol. 9, Núm. 10, pp. 671-673

  3. Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: Final results from a phase II study

    British Journal of Cancer, Vol. 97, Núm. 9, pp. 1206-1210

2002

  1. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine

    Cancer, Vol. 95, Núm. 4, pp. 751-757

2000

  1. Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer

    European Journal of Cancer, Vol. 36, Núm. SUPPL. 2, pp. 17-25

1998

  1. Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC)

    Lung Cancer, Vol. 22, Núm. 2, pp. 139-148